Diagnosis of APC resistance in patients on standard or low molecular weight heparin.
Gilmore
G
G
Thom
J
J
Baker
R I
RI
D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000494:pharmacology* / Q000627:therapeutic use; D017985:Dalteparin / Q000494:pharmacology* / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000494:pharmacology* / Q000627:therapeutic use; D004198:Disease Susceptibility; D005166:Factor V Deficiency / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D005188:False Negative Reactions; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D019763:Heparin Lyase; D006497:Heparan Sulfate / Q000494:pharmacology* / Q000627:therapeutic use; D006579:Heterozygote; D006801:Humans; D010314:Partial Thromboplastin Time; D011133:Polysaccharide-Lyases / Q000494:pharmacology; D011486:Protein C / Q000502:physiology*; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D017985:Dalteparin; D003871:Dermatan Sulfate; D006493:Heparin; D019763:Heparin Lyase; D006497:Heparan Sulfate; D011133:Polysaccharide-Lyases; D011486:Protein C; D011933:Reagent Kits, Diagnostic; C035838:danaparoid